The involvement of aldosterone on vascular insulin resistance: Implications in obesity and type 2 diabetes

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Bruder Nascimento, Thiago ^a   Da Silva, Marcondes A B ^a   Tostes, Rita C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aldosterone; Cardiovascular disease; Insulin resistance; Vascular dysfunction

Indexed keywords

ALDOSTERONE;

ALDOSTERONE RELEASE; ARTICLE; BIOAVAILABILITY; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR INSULIN RESISTANCE;

EID: 84907972331     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-90     Document Type: Article

References (86)

1. Extrarenal effects of aldosterone. Nguyen Dinh Cat A, Jaisser F, Curr Opin Nephrol Hypertens 2012 21 suppl2 147 156 22240440
2. Aldosterone synthase inhibitors in cardiovascular and renal diseases. Namsolleck P, Unger T, Nephrol Dial Transplant 2014 29 suppl1 62 i68 24493871
3. Aldosterone in the brain. Geerling JC, Loewy AD, Am J Physiol Renal Physiol 2009 297 suppl3 559 F576 19261742
4. Mechanisms of mineralocorticoid action. Fuller PJ, Young MJ, Hypertension 2005 46 6 1227 1235 10.1161/01.HYP.0000193502.77417.17 16286565
5. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Tallec LP, Lombès M, Nucl Recept Signal 2007 30 5 012
6. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, Feldman RD, Hypertension 2011 57 442 451 10.1161/HYPERTENSIONAHA.110.161653 21242460
7. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Callera GE, Yogi A, Briones AM, Montezano AC, He Y, Tostes RC, Schiffrin EL, Touyz RM, Cardiovasc Res 2011 1 suppl 4 720 731
8. Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte. Bienvenu LA, Reichelt ME, Delbridge LM, Young MJ, Clin Sci (Lond) 2013 125 9 409 421 10.1042/CS20130050 23829554
9. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM, Hypertension 2012 59 5 1069 1078 10.1161/HYPERTENSIONAHA.111.190223 22493070
10. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ, Arterioscler Thromb Vasc Biol 2014 34 2 355 364 10.1161/ATVBAHA.113.302854 24311380
11. Possible involvement of Rho-kinase in aldosterone-induced vascular smooth muscle cell remodeling. Miyata K, Hitomi H, Guo P, Zhang GX, Kimura S, Kiyomoto H, Hosomi N, Kagami S, Kohno M, Nishiyama A, Hypertens Res 2008 31 7 1407 1413 10.1291/hypres.31.1407 18957812
12. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC, Circulation 2004 8 suppl 22 2792 2800
13. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, Yoshizumi M, Hypertension 2005 46 4 1046 1052 10.1161/01.HYP.0000172622.51973.f5 16087789
14. Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK. Fu GX, Xu CC, Zhong Y, Zhu DL, Gao PJ, Endocrine 2012 42 3 676 683 10.1007/s12020-012-9675-2 22588951
15. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, Paradis P, Schiffrin EL, Circ Res 2009 23 suppl. 9 852 859
16. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL, Hypertension 2005 45 4 773 779 10.1161/01.HYP.0000154365.30593.d3 15699470
17. Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Mii S, Khalil RA, Morgan KG, Ware JA, Kent KC, Am J Physiol 1996 270 142 H150 8769745
18. Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. Bruder-Nascimento T, Chinnasamy P, Riascos-Bernal DF, Cau SB, Callera GE, Touyz RM, Tostes RC, Sibinga NE, J Mol Cell Cardiol 2014 66 18 26 24445059
19. The role of aldosterone in the metabolic syndrome. Briet M, Schiffrin EL, Curr Hypertens Rep 2011 3 163 172
20. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ, J Am Coll Cardiol 2005 45 1243 1248 10.1016/j.jacc.2005.01.015 15837256
21. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E, Eur Heart J 2012 33 191 202 10.1093/eurheartj/ehr176 21719456
22. Role of aldosterone and angiotensin II in insulin resistance: an update. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G, Clin Endocrinol (Oxf) 2009 71 1 6 10.1111/j.1365-2265.2008.03498.x 19138313
23. Plasma aldosterone concentration in the patient with diabetes mellitus. Hollenberg NK, Stevanovic R, Agarwal A, Lansang MC, Price DA, Laffel LM, Williams GH, Fisher ND, Kidney Int 2004 65 4 1435 1439 10.1111/j.1523-1755.2004.00524.x 15086486
24. Increased aldosterone/renin quotient in obese hypertensive women: a novel role for low-density lipoproteins? Lamounier-Zepter V, Rotthoff T, Ansurudeen I, Kopprasch S, Scherbaum WA, Ehrhart-Bornstein M, Bornstein SR, Horm Metab Res 2006 38 7 471 475 10.1055/s-2006-948137 16933186
25. Increased aldosterone levels in a model of type 2 diabetes mellitus. Fredersdorf S, Endemann DH, Luchner A, Heitzmann D, Ulucan C, Birner C, Schmid P, Stoelcker B, Resch M, Muders F, Riegger GA, Weil J, Exp Clin Endocrinol Diabetes 2009 117 1 15 20 10.1055/s-2008-1073128 18726873
26. Oxidative stress and diabetic vascular complications. Giugliano D, Ceriello A, Paolisso G, Diabetes Care 1996 19 3 257 267 10.2337/diacare.19.3.257 8742574
27. Vascular dysfunction in diabetes mellitus. Feener EP, King GL, Lancet 1997 350 1 I9 SI13 9250277
28. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Creager MA, Lüscher TF, Cosentino F, Beckman JA, Circulation 2003 23 suppl. 12 1527 1532
29. The endothelium and vascular inflammation in diabetes. Hartge MM, Unger T, Kintscher U, Diab Vasc Dis Res 2007 4 2 84 88 17654441
30. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, Ihara G, Fujita Y, Ugawa T, Kohno M, Hypertension 2007 50 750 755 10.1161/HYPERTENSIONAHA.107.093955 17646573
31. Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells. Tanabe A, Naruse M, Arai K, Naruse K, Yoshimoto T, Seki T, Imaki T, Kobayashi M, Miyazaki H, Demura H, J Endocrinol Invest 1998 21 10 668 672 10.1007/BF03350796 9854682
32. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Wong WT, Tian XY, Xu A, Ng CF, Lee HK, Chen ZY, Au CL, Yao X, Huang Y, Antioxid Redox Signal 2010 15 suppl. 6 757 768
33. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA, Gariani K, Martin PY, Eur J Intern Med 2014 25 2 173 176 10.1016/j.ejim.2013.11.007 24315413
34. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators, Lancet 2000 355 253 259 10675071
35. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R1, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, J Am Coll Cardiol 2013 22 suppl. 17 1585 1593
36. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators, N Engl J Med 1999 341 709 717 10.1056/NEJM199909023411001 10471456
37. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, N Engl J Med 2003 348 1309 1321 10.1056/NEJMoa030207 12668699
38. Adipose tissue, inflammation, and cardiovascular disease. Berg AH, Scherer PE, Circ Res 2005 96 939 949 10.1161/01.RES.0000163635.62927.34 15890981
39. Mineralocorticoid receptors in vascular function and disease. McCurley A, Jaffe IZ, Mol Cell Endocrinol 2012 350 256 265 10.1016/j.mce.2011.06.014 21723914
40. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Bender SB, McGraw AP, Jaffe IZ, Sowers JR, Diabetes 2013 62 suppl2 313 319 23349535
41. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA, J Clin Endocrinol Metab 2006 91 3457 3463 10.1210/jc.2006-0736 16822818
42. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA, Diabetes Care 2007 30 2349 2354 10.2337/dc07-0525 17575088
43. Aldosterone status associated with insulin resistance in patients with heart failure data from the ALOFT study. Tsorlalis IK, Lewsey JD, Latini R, Maggioni AP, Solomon S, Pitt B, Connell JM, McMurray JJ, Heart 2007 95 1920 1924
44. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I, Cardiovasc Res 2009 84 164 172 10.1093/cvr/cvp191 19505930
45. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3 T3-L1 adipocytes. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T, Endocrinology 2009 150 1662 1669 10.1210/en.2008-1018 19095745
46. Genetic variation in aldosterone synthase predicts plasma glucose levels. Ranade K, Wu KD, Risch N, Olivier M, Pei D, Hsiao CF, Chuang LM, Ho LT, Jorgenson E, Pesich R, Chen YD, Dzau V, Lin A, Olshen RA, Curb D, Cox DR, Botstein D, Proc Natl Acad Sci U S A 2001 98 13219 13224 10.1073/pnas.221467098 11687612
47. The amino-acid sequence in the glycyl chain of insulin: I: the identification of lower peptides from partial hydrolysates. Sanger F, Thompson EO, Biochem J 1953 53 suppl3 353 366 13032078
48. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Goodfriend TL, Egan BM, Kelley DE, Prostaglandins Leukot Essent Fatty Acids 1999 60 suppl5-6 401 405 10471129
49. Fatty acids are potential endogenous regulators of aldosterone secretion. Goodfriend TL, Ball DL, Elliott ME, Morrison AR, Evenson MA, Endocrinology 1991 128 5 2511 2519 10.1210/endo-128-5-2511 2019263
50. Leptin signaling, adiposity, and energy balance. Jéquier E, Ann N Y Acad Sci 2002 967 379 388 12079865
51. Chronic leptin infusion increases arterial pressure. Shek EW, Brands MW, Hall JE, Hypertension 1998 31 pt 2 409 414 9453337
52. Human leptin has natriuretic activity in the rat. Jackson EK, Li P, Am J Physiol 1997 272 pt 2 333 F338 9087676
53. Evidence for a novel peripheral action of leptin as a metabolic signal to the adrenal gland: leptin inhibits cortisol release directly. Bornstein SR, Uhlmann K, Haidan A, Ehrhart-Bornstein M, Scherbaum WA, Diabetes 1997 46 1235 1238 10.2337/diab.46.7.1235 9200662
54. Leptin and the renin-angiotensin-aldosterone system. Bornstein SR, Torpy DJ, Hypertension 1998 32 376 377 10.1161/01.HYP.32.2.376 9719071
55. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Belin de Chantemèle EJ, Mintz JD, Rainey WE, Stepp DW, Hypertension 2011 58 suppl2 271 279 21690486
56. The amino-acid sequence in the glycyl chain of insulin. II: the investigation of peptides from enzymi hydrolysates. Sanger F, Thompson EO, Biochem J 1953 53 suppl3 366 374 13032079
57. Insulin and its receptor: structure, function and evolution. De Meyts P, Bioessays 2004 26 suppl12 1351 1362 15551269
58. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Fu Z, Gilbert ER, Liu D, Curr Diabetes Rev 2013 1 suppl1 25 53
59. Pittman I, Philipson L, Steiner D, (last edition: 2009 by Dhemy Padilla), Insulin biosynthesis, secretion, structure, and structure-activity relationships http://diabetesmanager.pbworks.com/w/page/17680216/Insulin%20Biosynthesis,%20Secretion,%20Structure,%20and%20StructureActivity%20Relationships#INSULINBIOGENESISANDMECHANISMOFRELEASE
60. Insulin: the structure in the crystal and its reflection in chemistry and biology. Blundell T, Dodson G, Hodgkin D, Mercola D, Adv Protein Chem 1972 1972 26 279 402
61. Capillary recruitment and its role in metabolic regulation: a focus on insulin action in skeletal muscle. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S, Am J Physiol 2003 284 241 E258
62. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S, Am J Physiol 2003 285 123 E129
63. The structure of 2Zn pig insulin at 1.5 A° resolution. Baker EN1, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DM, Hubbard RE, Isaacs NW, Reynolds CD, Sakabe K, Sakabe N, Vijayan NM, Phil Trans R Soc Lond B 1988 19 369 456
64. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Hartell NA, Archer HE, Bailey CJ, Biochem Pharmacol 2005 1 suppl5 781 790
65. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Kim JA1, Montagnani M, Koh KK, Quon MJ, Circulation 2006 113 1888 1904 10.1161/CIRCULATIONAHA.105.563213 16618833
66. Nitric oxide. Moncada S, J Hypertens 1994 12 35 S39
67. Adrenoreceptors and nitric oxide in the cardiovascular system. Conti V, Russomanno G, Corbi G, Izzo V, Vecchione C, Filippelli A, Front Physiol 2013 6 suppl4 321 eCollection
68. AKT phosphorylation is essential for insulin-induced relaxation of rat vascular smooth muscle cells. Lee JH, Ragolia L, Am J Physiol Cell Physiol 2006 291 suppl6 1355 C1365 16855220
69. Insulin resistance and hypertension. Sowers JR, Am J Physiol Heart Circ Physiol 2004 286 1597 H1602 10.1152/ajpheart.00026.2004 15072967
70. Levine TB, Levine AB, Metabolic Syndrome and Cardiovascular Disease Mishawaka, IN, USA: Saunders 1 2006 Print
71. Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor. Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A, Hitomi H, Arterioscler Thromb Vasc Biol 2012 32 suppl2 257 263 22173225
72. Analysis of insulin sensitivity in adipose tissue of patients with primary aldosteronism. Urbanet R, Pilon C, Calcagno A, Peschechera A, Hubert EL, Giacchetti G, Gomez-Sanchez C, Mulatero P, Toffanin M, Sonino N, Zennaro MC, Giorgino F, Vettor R, Fallo F, J Clin Endocrinol Metab 2010 95 suppl8 4037 4042 20484481
73. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Whaley-Connell A, Johnson MS, Sowers JR, Prog Cardiovasc Dis 2010 52 suppl5 401 409 20226958
74. Moderate dietary salt restriction increases vascular and systemic insulin resistance. Feldman RD, Schmidt ND, Am J Hypertens 1999 12 643 647 10.1016/S0895-7061(99)00016-3 10371376
75. Insulin-like growth factor I receptor α-subunit heterogeneity: evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. Moxham CP, Duronio V, Jacobs S, J Biol Chem 1989 264 13238 13244 2546949
76. Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors. Schumacher R, Mosthaf L, Schlessinger J, Brandenburg D, Ullrich A, J Biol Chem 1991 266 19288 19295 1655782
77. Relationship between β subunit ligand occupancy and α- subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. Frattali AL, Pessin JE, J Biol Chem 1993 268 7393 7400 8463272
78. The role of IGF-system in vascular insulin resistance. Arnqvist HJ, Horm Metab Res 2008 40 588 592 10.1055/s-0028-1082325 18792869
79. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. Zeng G, Quon MJ, J Clin Invest 1996 98 894 898 10.1172/JCI118871 8770859
80. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ, Circulation 2000 101 1539 1545 10.1161/01.CIR.101.13.1539 10747347
81. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). Montagnani M, Chen H, Barr VA, Quon MJ, J Biol Chem 2001 276 suppl32 30392 30398 11402048
82. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Abbas A, Imrie H, Viswambharan H, Sukumar P, Rajwani A, Cubbon RM, Gage M, Smith J, Galloway S, Yuldeshava N, Kahn M, Xuan S, Grant PJ, Channon KM, Beech DJ, Wheatcroft SB, Kearney MT, Diabetes 2011 60 suppl8 2169 2178 21677284
83. Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. Masano T, Kawashima S, Toh R, Satomi-Kobayashi S, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Yamashita T, Yokoyama M, Hirata K, Circ J 2008 72 suppl9 1512 1519 18724032
84. Insulin-like growth factor-1 receptor expression masks the antiinflammatory and glucose uptake capacity of insulin in vascular smooth muscle cells. Engberding N, San Martín A, Martin-Garrido A, Koga M, Pounkova L, Lyons E, Lassègue B, Griendling KK, Arterioscler Thromb Vasc Biol 2009 29 408 415 10.1161/ATVBAHA.108.181727 19122171
85. Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells. Cascella T, Radhakrishnan Y, Maile LA, Busby WH Jr, Gollahon K, Colao A, Clemmons DR, Endocrinology 2010 151 suppl12 5851 5864 20881255
86. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM, Nature 1999 10 suppl6736 601 605